<DOC>
	<DOCNO>NCT01067339</DOCNO>
	<brief_summary>AIM III prospective , randomize , double-blinded , placebo control trial . The study directly connect IRB 08-008161 specific aim National Institute Health ( NIH ) grant . Participants may either consent qualify AIM I AIM II ( IRB 08-008161 ) cardiac catheterization acetylcholine test Cardiac Catheterization Laboratory Mayo Clinic Rochester , Minnesota consider study .</brief_summary>
	<brief_title>Lipoprotein-associated Phospholipase A2 ( Lp-PLA2 ) Progenitor Cells Coronary Atherosclerosis Humans</brief_title>
	<detailed_description>The main goal AIM III ass quantify effect long-term administration darapladib 160 mg day , selective , reversible , orally active inhibitor plasma vascular Lp-PLA2 , coronary endothelial function , progression coronary atherosclerosis determine intravascular ultrasound ( IVUS ) , atherosclerosis patient early atherosclerosis . Patients evidence coronary endothelial dysfunction , determine intracoronary administration acetylcholine angiography IVUS , follow 6 month daily dose darapladib . Coronary endothelial function determine change coronary artery diameter coronary blood flow response intracoronary administration acetylcholine adenosine . The patient follow clinic 6 month . They follow-up angiography , assessment endothelial function , IVUS six month visit .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>1 . Patients undergo coronary angiography include endothelial function test medication acetylcholine cardiac catheterization laboratory Mayo Clinic . Patients may enrol AIM I AIM II IRB 08008161 : LpPLA2 , Progenitor Cells Atherosclerosis Humans '' . 2 . Male female age least 18 year , inclusive , screen . Female subject must postmenopausal use highly effective method avoidance pregnancy . The decision include exclude woman childbearing potential may make discretion investigator accordance local practice relation adequate contraception . 3 . Age great 18 age 85 1 . Current severe heart failure New York Heart Association class III IV ejection fraction le 40 % 2 . Unstable angina 3 . Myocardial infarction angioplasty within 6 month prior entry study 4 . Planned coronary revascularization ( PCI CABG ) 5 . Planned major surgical procedure 6 . Patients segment endothelial dysfunction le 10 mm length complete occlusion exclude . 7 . Angiographic exclusion criterion include leave main disease great 30 % stenosis angiogram , luminal diameter study vessel le 2.5 mm , severe tortuousity study vessel , relevant anatomical reason investigator deems inappropriate study . 8 . Current liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) evidence abnormal liver function test ( total bilirubin alkaline phosphatase &gt; 1.5 x upper limit normal ( UNL ) ; alanine transaminase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 x UNL hepatic abnormality opinion investigator would preclude subject participation study . 9 . Chronic acute kidney disease serum creatinine great equal 2 mg/dL estimate glomerular filtration rate &lt; 40 mL/min/1.73m2 , renal transplant status , history contrast nephropathy , 10 . Poorly control hypertension despite lifestyle modification pharmacotherapy . ( systolic BP &gt; 160 mm Hg and/or diastolic BP &gt; 110 mm Hg ) , 11 . Poorly control diabetes mellitus ( HbA1c &gt; 10 % ) , 12 . Current within 1 month use form corticosteroid , 13 . Severe asthma poorly control pharmacotherapy 14 . History anaphylaxis , anaphylactoid ( resemble anaphylaxis ) reactions 15 . Current lifethreatening condition vascular disease , alcohol drug abuse within last 6 month 16 . Malignancy within past 5 year , 17 . Positive pregnancy test ( female subject childbearing potential must urine βhuman chorionic gonadotropin ( hCG ) pregnancy test perform Screening and/or within 7 day prior randomization ) know pregnant lactating . 18 . Current plan chronic administration strong oral injectable cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) inhibitor . 19 . Subjects parent Japanese , Chinese , Korean ancestry must blood sample collected assessment LpPLA2 activity central laboratory prior randomization . Those LpPLA2 activity ≤10 nmol/min/mL exclude participation study . 20 . Previous exposure darapladib ( SB480848 ) . 21 . Use investigational device investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication , subject investigator deem unsuitable study 22 . Patients require treatment positive inotropic agent digoxin study 23 . Patients cerebrovascular accident within 6 month prior entry study 24 . Significant endocrine , hepatic renal disorder 25 . Local systemic infectious disease within 4 week prior entry study 26 . Mental instability 27 . Federal Medical Center inmates 28 . Hemoglobin le 12 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>coronary endothelial dysfunction</keyword>
	<keyword>coronary vasospasm</keyword>
</DOC>